REGENXBIO Inc. (RGNX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
38/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinRGNX / S&P 42.96% / 15.20% |
LoseRGNX / S&P 12.00% / 15.00% |
LoseRGNX / S&P 10.50% / 50.40% |
| 2026-Q11/3 |
LoseRGNX / S&P -41.81% / -4.33% |
LoseRGNX / S&P -43.96% / 11.30% |
WinRGNX / S&P 80.65% / 27.70% |
| 2025-Q42/3 |
WinRGNX / S&P 49.22% / 2.65% |
WinRGNX / S&P 104.54% / 9.00% |
LoseRGNX / S&P -18.26% / 13.40% |
| 2025-Q32/3 |
WinRGNX / S&P 17.54% / 8.12% |
WinRGNX / S&P 91.30% / 4.61% |
LoseRGNX / S&P -31.08% / 13.45% |
| 2025-Q22/3 |
WinRGNX / S&P 14.83% / 10.94% |
WinRGNX / S&P 74.95% / 4.83% |
LoseRGNX / S&P -34.79% / 10.63% |
| 2025-Q11/3 |
LoseRGNX / S&P -7.50% / -4.27% |
WinRGNX / S&P 80.70% / 4.98% |
LoseRGNX / S&P -47.19% / 10.57% |
| 2024-Q40/3 |
LoseRGNX / S&P -26.31% / 2.41% |
LoseRGNX / S&P -7.66% / 5.25% |
LoseRGNX / S&P -23.59% / 6.15% |
| 2024-Q30/3 |
LoseRGNX / S&P -10.34% / 5.89% |
LoseRGNX / S&P -15.14% / 5.89% |
LoseRGNX / S&P -16.19% / 6.11% |
| 2024-Q20/3 |
LoseRGNX / S&P -44.47% / 4.28% |
LoseRGNX / S&P -8.18% / 5.38% |
LoseRGNX / S&P -16.90% / 5.12% |
| 2024-Q11/3 |
WinRGNX / S&P 17.38% / 10.56% |
LoseRGNX / S&P -20.90% / 5.71% |
LoseRGNX / S&P -6.08% / 5.59% |
| 2023-Q40/3 |
LoseRGNX / S&P 9.05% / 11.69% |
LoseRGNX / S&P -19.94% / 6.81% |
LoseRGNX / S&P -7.53% / 7.78% |
| 2023-Q30/3 |
LoseRGNX / S&P -17.66% / -3.27% |
LoseRGNX / S&P -79.30% / 7.52% |
LoseRGNX / S&P -448.26% / -5.03% |
| 2023-Q20/3 |
LoseRGNX / S&P 5.71% / 8.74% |
LoseRGNX / S&P -79.98% / 9.50% |
LoseRGNX / S&P -401.43% / -8.57% |
| 2023-Q10/3 |
LoseRGNX / S&P -16.62% / 7.50% |
LoseRGNX / S&P -76.85% / 10.77% |
LoseRGNX / S&P -369.40% / -15.69% |
| 2022-Q40/3 |
LoseRGNX / S&P -14.19% / 7.56% |
LoseRGNX / S&P -76.03% / 11.88% |
LoseRGNX / S&P RGNX unavailable / -17.99% |
| 2022-Q32/3 |
WinRGNX / S&P 7.00% / -4.88% |
WinRGNX / S&P 415.41% / 13.47% |
LoseRGNX / S&P RGNX unavailable / -1.41% |
| 2022-Q21/3 |
LoseRGNX / S&P -25.58% / -16.10% |
WinRGNX / S&P 200.29% / 13.71% |
LoseRGNX / S&P RGNX unavailable / 11.04% |
| 2022-Q12/3 |
WinRGNX / S&P 1.50% / -4.60% |
WinRGNX / S&P 204.02% / 15.97% |
LoseRGNX / S&P RGNX unavailable / 42.23% |
| 2021-Q41/3 |
LoseRGNX / S&P -21.99% / 11.03% |
WinRGNX / S&P 204.30% / 15.00% |
LoseRGNX / S&P RGNX unavailable / 96.40% |
| 2021-Q31/3 |
WinRGNX / S&P 7.90% / 0.58% |
LoseRGNX / S&P -35.72% / 10.77% |
LoseRGNX / S&P RGNX unavailable / 69.42% |
| 2021-Q22/3 |
WinRGNX / S&P 13.90% / 8.55% |
WinRGNX / S&P 165.79% / 6.58% |
LoseRGNX / S&P RGNX unavailable / 51.81% |
| 2021-Q11/3 |
LoseRGNX / S&P -24.80% / 6.17% |
WinRGNX / S&P 199.67% / -1.06% |
LoseRGNX / S&P RGNX unavailable / 7.39% |
| 2020-Q42/3 |
WinRGNX / S&P 64.83% / 12.15% |
WinRGNX / S&P 338.70% / -3.72% |
LoseRGNX / S&P RGNX unavailable / -33.42% |
| 2020-Q31/3 |
LoseRGNX / S&P -25.28% / 8.93% |
WinRGNX / S&P 125.54% / -2.04% |
LoseRGNX / S&P RGNX unavailable / -27.10% |
| 2020-Q21/3 |
LoseRGNX / S&P 13.74% / 20.54% |
WinRGNX / S&P 10.63% / -0.46% |
LoseRGNX / S&P RGNX unavailable / -27.11% |
| 2020-Q10/3 |
LoseRGNX / S&P -20.97% / -19.60% |
LoseRGNX / S&P -40.24% / 3.47% |
LoseRGNX / S&P RGNX unavailable / -14.75% |
| 2019-Q41/3 |
WinRGNX / S&P 15.08% / 9.07% |
LoseRGNX / S&P -83.88% / 5.36% |
LoseRGNX / S&P -191.20% / 2.99% |
| 2019-Q30/3 |
LoseRGNX / S&P -30.70% / 1.70% |
LoseRGNX / S&P -64.26% / 5.02% |
LoseRGNX / S&P -179.74% / 0.21% |
| 2019-Q20/3 |
LoseRGNX / S&P -10.36% / 4.30% |
LoseRGNX / S&P -68.80% / 6.64% |
LoseRGNX / S&P -166.20% / 8.65% |
| 2019-Q11/3 |
WinRGNX / S&P 36.62% / 13.65% |
LoseRGNX / S&P -38.88% / 8.12% |
LoseRGNX / S&P -178.42% / 14.29% |
| 2018-Q41/3 |
LoseRGNX / S&P -44.44% / -13.52% |
WinRGNX / S&P 2002.42% / 9.05% |
LoseRGNX / S&P -214.98% / 18.23% |
| 2018-Q31/3 |
LoseRGNX / S&P 5.23% / 7.71% |
WinRGNX / S&P 1688.91% / 10.21% |
LoseRGNX / S&P RGNX unavailable / 19.06% |
| 2018-Q22/3 |
WinRGNX / S&P 140.37% / 3.43% |
WinRGNX / S&P 1889.12% / 9.03% |
LoseRGNX / S&P RGNX unavailable / 14.46% |
| 2018-Q11/3 |
LoseRGNX / S&P -10.23% / -0.76% |
WinRGNX / S&P 2960.18% / 7.68% |
LoseRGNX / S&P RGNX unavailable / 12.46% |
| 2017-Q41/3 |
LoseRGNX / S&P 0.91% / 6.64% |
WinRGNX / S&P 126.48% / 7.03% |
LoseRGNX / S&P RGNX unavailable / 13.82% |
| 2017-Q32/3 |
WinRGNX / S&P 66.84% / 4.48% |
WinRGNX / S&P 36.89% / 5.68% |
LoseRGNX / S&P RGNX unavailable / 17.57% |
| 2017-Q21/3 |
LoseRGNX / S&P 2.33% / 3.09% |
WinRGNX / S&P 5.77% / 4.83% |
LoseRGNX / S&P RGNX unavailable / 17.74% |
| 2017-Q10/3 |
LoseRGNX / S&P 4.04% / 6.07% |
LoseRGNX / S&P -36.67% / 3.67% |
LoseRGNX / S&P RGNX unavailable / 13.32% |
| 2016-Q41/3 |
WinRGNX / S&P 32.41% / 3.82% |
LoseRGNX / S&P -39.58% / 2.09% |
LoseRGNX / S&P RGNX unavailable / 7.05% |
| 2016-Q32/3 |
WinRGNX / S&P 75.13% / 3.85% |
WinRGNX / S&P 70.92% / 0.20% |
LoseRGNX / S&P RGNX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RGNX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 4.93% | 20.78% |
| Annualized return | 4.93% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RGNX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -72.13% | 83.14% |
| Annualized return | -22.55% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | RGNX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -20.05% | 319.30% |
| Annualized return | -2.21% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |